Free Trial

Senseonics Q1 2023 Earnings Report

Senseonics logo
$0.68 -0.03 (-4.33%)
As of 01:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Senseonics EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.03
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Senseonics Revenue Results

Actual Revenue
$4.14 million
Expected Revenue
$3.05 million
Beat/Miss
Beat by +$1.09 million
YoY Revenue Growth
N/A

Senseonics Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

Senseonics Earnings Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Senseonics reports Q4 EPS (2c), consensus (3c)
Senseonics, Ascensia integrate SweetSpot with Eversense 365 CGM
See More Senseonics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Senseonics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Senseonics and other key companies, straight to your email.

About Senseonics

Senseonics (NYSE:SENS), a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

View Senseonics Profile

More Earnings Resources from MarketBeat